Pfizer “outperform”

01/06/06 - Bear Stearns

NEW YORK, January 6 (newratings.com) – Analyst John Boris of Bear Stearns reiterates his "outperform" rating on Pfizer Inc (PFE). The target price is set to $30.

In a research note published yesterday, the analyst mentions that the undervaluation of the launch of Lyrica has created a buying opportunity for the company’s stock. The analyst estimates Lyrica’s global sales for 2010 at $2.4 billion. There is incremental upside of more than $2 billion to Lyrica’s sales, which would boost the 2010 EPS estimates for Pfizer by $0.14 and the five-year CAGR estimate by 100bps to 11%, Bear Stearns adds.